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INTRODUCTION
Bisphenol A (BPA, 4,4’-(propane-2,2-diyl)diphenol), a ma-
jor component of epoxy resins and polycarbonate plastics, is 
broadly used in the manufacture of plastic wares, coating ma-
terials for food and beverage containers, and thermal receipt 
papers (Le et al., 2008; Swedenborg et al., 2009; Goodman 
et al., 2017). Average daily exposure of adult to BPA was es-
timated to fall in the range of 0.1 to 5 μg/kg body weight per 
day (Vandenberg et al., 2013), which would persist throughout 
the whole life. Indeed, BPA was detected in the urine in most 
adults in US and Korea (>90%) with the average concentra-
tion of 1.28-2.64 μg/L (Calafat et al., 2008; Vandenberg et al., 
2010; Miyaguchi et al., 2015; Park et al., 2016).
Generally, the toxicity of BPA is considered rather weak 
which was based on conventional toxicity assessments in ro-
dents. US Environment Protection Agent determined NOAEL 
of BPA at 50 mg/kg/day while European Union set it at 5 mg/
kg/day. However, concerns have been raised on the endocrine 
disrupting effects and the potential carcinogenesis from expo-
sure to low-dose BPA, which generally do not follow monotonic 
dose response relationship; therefore, effects at lower doses 
could not be neglected. Indeed, BPA is known to induce cellu-
lar alterations associated with proliferation and carcinogenicity 
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Increasing concern is being given to the association between risk of cancer and exposure to low-dose bisphenol A (BPA), espe-
cially in young-aged population. In this study, we investigated the effects of repeated oral treatment of low to high dose BPA in 
juvenile Sprague-Dawley rats. Exposing juvenile rats to BPA (0, 0.5, 5, 50, and 250 mg/kg oral gavage) from post-natal day 9 for 90 
days resulted in higher food intakes and increased body weights in biphasic dose-effect relationship. Male mammary glands were 
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greater at early age (e.g., 210-fold in Cmax, and 26-fold in AUC at 50 mg/kg in male on day 1 over day 90) and in females (e.g., 4-fold 
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through interacting with multiple hormone receptors (Zoeller 
et al., 2005; vom Saal et al., 2007; Vogel, 2009; Kwintkiewicz 
et al., 2010; Sui et al., 2012), and genetic/epigenetic toxicity 
(Tsutsui et al., 1998; Iso et al., 2006; Izzotti et al., 2009). Due 
to this, the safety of BPA on young children is questioned since 
these populations are extremely sensitive to endocrine disrup-
tion and at a risk of higher exposure due to widespread use 
of plastic nursing wares, toys and the inappropriate behaviors 
like pica and suckling (Edginton and Ritter, 2009).
Many researches have been undertaken to investigate the 
toxicity of BPA on juvenile populations and demonstrated po-
tential harmful effects of BPA exposure on neuromuscular sys-
tem (Jones et al., 2016), central nerve system and behavior 
(Rebuli et al., 2014, 2015), adipogenicity and energy metabo-
lism (Rönn et al., 2013), heart (Ljunggren et al., 2016), immune 
responses (Ménard et al., 2014), endocrine system (Ahmed, 
2016), the development of reproductive organs (Delclos et 
al., 2014) and liver (Xia et al., 2014). In most of these studies, 
however, bona fide signs of carcinogenicity could not be shown 
for low doses of BPA. Doses of BPA adopted in these studies 
ranged from 2.5 to 5,000 μg/kg bw/day, which are most prob-
ably designed to cover doses lower than 5 mg/kg, the most 
stringent NOAEL in EU (Park et al., 2016), and at the same 
time, the highest human exposure level reported; 5 μg/kg and 
current TDI, 50 μg/kg. At these low dose exposure scenarios, 
only minimal signs of weight gains and metabolic abnormality 
(Marmugi et al., 2012), increased hepatocyte apoptosis (Xia 
et al., 2014), behavioral changes, and neurological alterations 
were significant enough for observation. To elucidate the risk 
of low-dose exposure to BPA in young children, we consid-
ered it crucial to adopt extended dosing periods starting from 
early ages with toxicokinetic profiles of BPA over maturation to 
adult, to address functional maturation of liver.
Herein, BPA was repeatedly administered to juvenile SD 
rats from post-natal day 6 through their adulthood through 
toxicokinetic examinations. To this end, we adopted a sen-
sitive analytical tool, LC/MSMS (limit of detection about 0.5 
ppb), and immunohistochemical analysis with Ki-67 antibody 
to closely examine the signs of proliferation of liver to provide 
a novel insight for understanding the potential adverse health 
effects of BPA on young children. 
MATERIALS AND METHODS
Materials
Bisphenol A (BPA, CAS 80-05-7) was purchased from Sig-
ma-Aldrich (St. Louis, CA, USA). Dose formulations were pre-
pared on the day of dosing with 0.3% carboxyl methylcellulose 
for oral gavage administration as appropriate. LC-MS grade 
water (Tedia, NJ, USA), acetonitrile (Burdick & Jackson, MI, 
USA), and ammonium acetate (Sigma-Aldrich) were used in 
the mobile phase of LC system.
Animals and husbandry
F0 generation male and female Sprague-Dawley (Crl:CD) 
rats were obtained from Orient Bio Inc (Gyeonggi, Korea). For 
obtaining pregnant animals, two females were placed in the 
cage with one male overnight. F1 generation male and female 
pups were selected on postnatal day (PND) 4. All procedures 
were in compliance with Animal Welfare Act and Guide for the 
Care and Use of Laboratory Animals (by ILAR publication) 
and assessed by the Institutional Animal Care and Use Com-
mittee (IACUC) of KIT (The approval number is 1605-0157). 
The animal room was maintained in a controlled environment 
(temperature: 23 ± 3°C, humidity: 30-70%, light cycle: 12-
hour light/12-hour dark cycle, light intensity: 150-300 Lux, air 
changes: 10 to 20 times/hour). A standard rodent pellet diet 
(Lab Diet® #5053 PMI Nutrition International, USA; irradiated 
by gamma-ray) and filtered, ultraviolet light-irradiated munici-
pal tap water were provided to the animals ad libitum. 
Animal experiments
PND 4 rats were considered to be equivalent to preterm hu-
man babies (Bowman et al., 2011) and the PND 7 are believed 
to be similar to humans at birth (Beck et al., 2006). On PND 4, 
each pups are cross-fostered between litters such that each 
litter is comprised of pups originating from at least 6 different 
litters, with no litter-mates of the same sex, and containing no 
pups from the original litter. Pups were assigned to toxicology 
and toxicokinetic groups. Male and female pups were admin-
istered with BPA by oral gavage once daily at dose level of 0, 
0.5, 5, 50 and 250 mg/kg/day from PND 6 to 96 for 13-week. 
Parameters including mortality, clinical sign, body weight, food 
consumption, sexual maturation, organ weight, clinical pathol-
ogy, macro- and microscopic findings were examined. For 
treatment groups, approximately 0.5 mL of blood were seri-
ally taken form caudal vein and put into blood collecting tubes 
containing EDTA-2K before (0), and at 0.25, 0.5, 1, 2, 4, 8 and 
24 hours after administration of BPA on day 1 and day 91, re-
spectively. Serum was collected and then stored in -80°C prior 
to analysis. Liver tissues were fixed in formalin, embedded in 
paraffin, and undergone section to stain with H&E. 
Ki-67 immunohistochemistry and quantitative analysis
For examination of bile duct cell proliferation capacity, we 
processed immunohistochemical staining for Ki-67 as de-
scribed previously (Kim et al., 2016). To perform immunohis-
tochemistry, samples were fixed in 4% paraformaldehyde and 
then embedded in paraffin. The sections were deparaffinized 
and rehydrated sequentially. Antigen retrieval was carried out 
using pH 6.0 Target Retrieval solution (DAKO, Carpinteria, CA, 
USA) in a pressure cooker for 15 min. After cooling for more 
than 1 h on ice, the sections were incubated in 3% H2O2 for 30 
min to block endogeneous peroxidase activity. The sections 
were washed twice with PBS and incubated with Protein block 
serum-free (DAKO) for 2 h at 25°C to reduce non-specific sig-
nal. Sections were incubated overnight at 4°C with primary 
antibody specific for Ki-67 (abcam, Cambridge, UK) at a 1:200 
dilution. After washing three times with PBS, the sections were 
incubated for 15 min with HRP-conjugated rabbit secondary 
antibody (DAKO) at 25°C. For immunohistochemistry, DAB 
(DAKO) was used for antibody development and Mayer’s He-
matoxylin (DAKO) was used for counter staining.
For quantitative analysis, all bile duct area in each group 
samples was captured using Olympus BX43 microscope 40× 
lens (Olympups Optical Co., Tokyo, Japan). Using the Image 
J (National Institutes of Health, USA), we counted total cell of 
each group bile duct and calculated the percentages of Ki-67 
positive cells, respectively. 
Toxicokinetic analysis
The BPA calibration standards were prepared firstly by 
making 300 ppm stock solution of the substance in methanol. 
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Then, the list of standards was prepared by spiking blank rat 
serum and acetonitrile to obtain standards ranging from 0.5 
ppb to 100 ppm. The standards then centrifuged at 14,000 × g 
for 5 min at 4°C, and later the supernatant was used.
Fifty microliter aliquot of samples were treated with aceto-
nitrile (1:4, v/v), and centrifuged at 14,000 x g for 5 minutes 
at 4°C in order to separate protein (Johnson et al., 2010). 
BPA was separated using Agilent 1290 Ultra Performance 
Liquid Chromatography with Thermo Hypersil GOLD aQ 100 
mm×2.1 mm column (1.9 μm particle size), and two mobile 
phases: 1 mM ammonium acetate in water (A) and acetonitrile 
(B) in isocratic elution. Injection volume was 3 μL at a flow rate 
of 0.3 mL/min and a column temperature of 50°C. BPA was 
detected and quantified using Agilent 6490 triple quad (QQQ) 
LC/MS multiple reaction monitoring (MRM) mode in the nega-
tive ionization, showing that the patterns of ion dissociation 
matched with standards (Buscher et al., 2015; Wilczewska 
et al., 2016). The parent and daughter m/z for BPA detection 
and quantification in this study were 227.10 and 211.95, re-
spectively at retention time of 1.4 min. LOD and LOQ were 
obtained with the value of 0.55 ppb and 1.68 ppb, respectively. 
For obtaining pharmacokinetic parameters (Cmax, Tmax and 
area under curve), non-compartment model was assumed and 
calculated with calculated with WINNONLIN ver. 5.2 (Phar-
sight, Sunnyvale, CA, USA) as described previously (Noh et 
al., 2016). 
Statistics
Statistical analyses for comparisons of the various dose 
groups with the vehicle control group were conducted using 
Pristima System (Version 6.4, Xybion Medical Systems Cor-
poration, USA). Difference from control (0 mg/kg) group was 
examined using Student t-test. Multiple comparison tests for 
different dose groups were conducted. Variance of homoge-
neity was examined using the Bartlett’s Test. Homogeneous 
data was analyzed using the Analysis of Variance (ANOVA) 
and the significance of inter-group differences were analyzed 
using Dunnett’s Test. Heterogeneous data was analyzed us-
ing Kruskal-Wallis Test and the significance of inter-group 
differences between the control and treated groups were as-
sessed using Dunn’s Rank Sum Test. 
RESULTS
Effects of oral treatment of BPA on body weight change 
and food consumption
Increased body weight and food consumption were noted 
in 5 mg/kg male group from 8 weeks of age which persisted 
until the end of treatment (13 weeks, Fig. 1A, 1B). Interest-
ingly, other dose groups (0.5, 50 and 250 mg/kg) in male and 
all dose groups in female did not showed any effects on body 
weights. However, increased food consumption was noted 
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Fig. 1. Body weight and food consumption of juvenile rats exposed to BPA for 90 days. Body weight of male (A) and female (B) rats orally 
exposed to BPA at 0, 0.5, 5, 50 and 250 mg/kg/day. Food consumptions of male (C) and female (D) rats. Data are mean ± SD of 10 ani-
mals. *p<0.05, **p<0.01, Student t-test for the difference from 0 mg/kg/day.
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sporadically across 50 and 250 mg/kg BPA in males and con-
sistently in 250 mg/kg BPA in female (Fig. 1C, 1D). 
Effects of oral treatment of BPA on hematology and blood 
chemistry
Hematology revealed that white blood cell (WBC) and ab-
solute lymphocyte (LYM) were increased at 50 and 250 mg/
kg in both sexes. Additionally, relative LYM was elevated at 
250 mg/kg in males (Supplementary Table 1). Absolute mono-
cyte (MON) was increased at dose higher than 5 mg/kg in 
females. Absolute and relative large unstained cells (LUC) 
were increased at 5 mg/kg in males, and absolute LUC were 
increased at 50 and 250 mg/kg in females. Activated partial 
thromboplastin time (APTT) was decreased at dose higher 
than 50 mg/kg in males and 5 mg/kg in females. Blood chem-
istry showed that creatinine (CRE) was decreased at doses 
higher than 0.5 mg/kg in male (Supplementary Table 2). Albu-
min/globulin (A/G) ratio was decreased at doses higher than 
50 mg/kg in male and 5 mg/kg in female, respectively. Total 
bilirubin (TBIL) was increased at 0.5, 50 and 250 mg/kg in 
males, and at doses higher than 5 mg/kg in female. At 250 
mg/kg group, increased γ-glutamyl transpeptidase (GGT) and 
Alkaline phosphatase (ALP) were observed in males and fe-
males, respectively.
Other statistically significant changes noted in dosing 
groups compared with the control were not considered BPA-
related, as these values were within an acceptable range for 
biological variation.
Effects of oral treatment of BPA on the sexual maturation 
and organ weights
To examine the effects of BPA on sexual maturation of male 
and female juvenile rats, prepuptial separation and vaginal 
opening time were evaluated respectively (Supplementary Ta-
ble 3). Female exposed to high dose BPA (250 mg/kg) showed 
premature vaginal opening (30.4 ± 0.52 day vs 32.2 ± 1.75, 
p<0.01), alluding the pro-estrogenic effects of BPA. The body 
weight at the time of vaginal opening was significantly lighter 
in the BPA (250 mg/kg) exposed group, alluding the premature 
sexual development. 
Measurement of absolute (Supplementary Table 4) and rel-
ative organ weights (Supplementary Table 5) revealed that the 
lung of male rats dosed with 50 and 250 mg/kg BPA showed 
increased weights. 
Histopathological examination of the liver of rats ex-
posed to BPA
To analyze the characteristics of BPA effects in the liver, 
morphological changes were examined for male animals by a 
pathologist (Table 1). Fig. 2 summarizes representative patho-
logic findings present in the 0.5 mg/kg BPA treated group 
showing altered cell foci, bile duct hyperplasia and persistent 
focal inflammatory cell infiltration. As shown in Fig. 2, the eo-
sinophilic altered cell foci were observed in BPA 0.5 mg/kg 
and 5 mg/kg male group (Fig. 2A, 2D, arrow head). 0.5 mg/kg 
group also showed bile duct hyperplasia (Fig. 2B, arrow head) 
with focal inflammatory cell infiltration (Fig. 2B, asterisk). The 
bile duct hyperplasia in the BPA treated group showed distinct 
pathological features that the proliferative epithelial cell islets 
of bile duct significantly extended into the portal triad mesen-
chyma without lymphocyte infiltration (Fig. 2B, arrow head). 
Multi focal lymphocytic inflammatory cells infiltration was also 
Table 1. Histopathological findings and grading of the liver of males
Dose level (mg/kg/day) 0 0.5 5 50 250
No. of animals observed 5 5 5 5 5
Altered cell foci + (0/5) + (1/5) + (0/5) + (1/5) + (2/5)
++ (0/5) ++ (1/5) ++ (2/5) ++ (2/5) ++ (1/5)
+++ (0/5) +++ (0/5) +++ (0/5) +++ (1/5) +++ (2/5)
Bile duct hyperplasia + (0/5) + (3/5) + (1/5) + (1/5) + (0/5)
++ (0/5) ++ (1/5) ++ (2/5) ++ (2/5) ++ (2/5)
+++ (0/5) +++ (1/5) +++ (2/5) +++ (2/5) +++ (3/5)
Focal inflammation + (0/5) + (2/5) + (2/5) + (4/5) + (2/5)
++ (0/5) ++ (0/5) ++ (3/5) ++ (0/5) ++ (2/5)
+++ (0/5) +++ (0/5) +++ (0/5) +++ (1/5) +++ (1/5)
(  ): Number of animals, Affected animals/Total examined animals.
*
A
C
B
D
Fig. 2. Histopatholgical findings in the liver of BPA-treated juvenile 
rats. BPA 0.5 mg/kg: Photomicrograph of the eosinophilic altered 
cell foci (arrow head) with grade + (A), BPA 0.5 mg/kg: Photomicro-
graph of minimal bile duct hyperplasia (arrow head) with lympho-
cytic cell infiltration (asterisk) with grade ++ (B). BPA 0.5 mg/kg: 
Focal inflammatory cell infiltration with grade + (C). BPA 5 mg/kg: 
Photomicrograph of the eosinophilic altered cell foci (arrow head) 
with grade ++ (D). (Bar=50 μm).
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observed in liver parenchyma (Fig. 2C). Fig. 2D shows that 
eosinophilic altered cell foci graded two plus in 5 mg/kg group 
(arrow head).
Systemic exposure to BPA after oral treatment of BPA on 
day 1 and day 91
To examine the toxicokinetic behavior of BPA in juvenile 
rats, population pharmacokinetics was applied since full-time 
coursed sampling is impossible in juvenile rats due to lim-
ited blood volume. For each time point over 0 to 24 h after 
administration, 4 plasma samples were collected from 4 ani-
mals. During day 1 administration, each experimental group 
has similar BPA concentration-time curve pattern, with Tmax 
obtained mostly within 1 h after administration (Fig. 3A, 3B). 
Second peaks were observed in high dose groups (250 mg/kg 
male and female), indicating the entero-hepatic recirculation 
of BPA. Area under curve (AUC) and Cmax exhibited non-linear 
(supra-linear) dose-response relationship (Table 2), suggest-
ing that clearance pathways might be easily saturated at high 
doses. In gender-wise comparison, female rats showed higher 
BPA concentrations and exposure.
Similar patterns but with greatly reduced levels of BPA were 
observed on day 91 (Fig. 3C, 3D). On day 91, BPA was not de-
tectable in 0.5 and 5 mg/kg in male and 0.5 mg/kg in female, 
reflecting that clearance might be considerably increased dur-
ing maturation into adulthood.
DISCUSSION
This study demonstrated that BPA, when administered to 
juvenile rats for 90 days even at doses as low as 0.5 mg/kg/
day, induces altered cell foci, bile duct hyperplasia, and persis-
tent focal inflammatory cell infiltration in the liver, providing a 
strong evidence that risk of cancer is associated with low-dose 
BPA exposure. Carcinogenic and proliferative effects of BPA 
have been a topic of intense debate. Recently, Weinhouse et 
al. (2014) reported that perinatal exposure to 50 mg/kg BPA 
could induce neoplastic and pre-neoplastic lesions in mice 
liver at the age of 10 months. In particular, they observed a hy-
perplastic nodule around bile duct, which is in accordance with 
our findings. However, mice are not a standard species for 
repeated dose toxicity or carcinogenicity bioassay. Also, the 
dose level is exceedingly high considering that the average 
human exposure remains below 10 μg/kg/day. In this context, 
we attempted to add an important line of evidence by show-
ing the proliferative effects of BPA in standard experimental 
animal species (rats) at lower dose levels (up to 0.5 mg/kg/
day, which can be calculated to human equivalent dose of 80 
μg/kg/day), in order to provide strong evidence for pro-hepato-
carcinogenic effects of BPA, which needs further investigation.
Mechanism behind BPA-induced bile duct proliferation re-
mains unclear in the results of the current study. However, 
both non-genotoxic and genotoxic pathways are likely to be 
involved in the proliferative effects of BPA. Generally, prolif-
erative effects of BPA is considered to emerge from its en-
docrine disrupting activities, since it could interact with mul-
tiple hormone receptors including estrogen (vom Saal et al., 
2007), androgen (Vogel, 2009), pregnane X receptors (Sui et 
al., 2012), thyroid (Zoeller et al., 2005), and peroxisome pro-
liferator-activated receptor-γ (Kwintkiewicz et al., 2010). Direct 
injury of DNA by BPA cannot be ruled out. Many studies have 
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Fig. 3. Bile duct proliferation in the liver of BPA-treated juvenile 
rats. Photomicrograph of the immunohistochemistry for Ki-67 to 
evaluate bile duct proliferation, BPA 0 mg/kg (A), 0.5 mg/kg with 
arrow heads indicating Ki-67+ cells (B) and 250 mg/kg (C). Ratio 
of Ki-67+ bile duct cells over total bile duct cells (mean ± SEM of 
counting in 7-45 sections). **p<0.01 One-way ANOVA followed by 
Dunnett’s post hoc analysis.
Table 2. Toxicokinetic parameters
Dose level (mg/kg/day)
0.5 5 50 250
Day 1 Day 91 Day 1 Day 91 Day 1 Day 91 Day 1 Day 91
Male
  Tmax (Tmax1/Tmax2, h) 0.5 - 0.25 - 1 1/8 1/8 1
  Cmax (Cmax1/Cmax2, nM) 14.7 - 86.6 - 8387.8 33.3/40.0 146,219.7/14,286.8 883.2
  Area under curve (AUC0-t, nmole*h/L) 17.1 - 105.8 - 12,834.2 493.8 269,943.3 2,369.4
Female
  Tmax (h) 0.25 - 0.25 0.25 0.5 1 1/8 0.5
  Cmax (nmole/L, nM) 7.5 - 130.0 10.9 34,635.6 108.0 121,141.4/56,091.0 2445.9
  Area under curve (AUC0-t, nmole*h/L) 1.9 - 89.3 4.4 19,961.1 123.0 773,664.0 3,088.5
*Parameters were calculated with average concentrations of each time point.
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shown that BPA induces the formation of DNA adducts (Izzotti 
et al., 2009), genetic mutations, cellular transformation (Tsut-
sui et al., 1998), and positive Comet assay results (Iso et al., 
2006), which may explain the bile duct proliferation observed 
in the current study, although further studies are required to 
clarify it. 
The systemic exposure to BPA was greater at the early age 
and in female than in male, suggesting the higher susceptibil-
ity of juvenile populations to BPA. It has been reported that 
the oral systemic bioavailability of BPA is low ranging around 
20% which is attributable to extensive metabolism to sulfate- 
or glucuronide-conjugated forms. The results from male rats 
dosed orally in the current study largely confirm the findings 
of previous investigators (Churchwell et al., 2014; Draganov 
et al., 2015) but Churchwell et al. (2014) showed only pooled 
data from both sexes. Our data provided remarkably different 
profiles between male and females, which may considerably 
expands the knowledge on the pharmacokinetic behaviors of 
BPA. Cmax and AUC of BPA augmented exponentially as dos-
es increase, indicating that the clearance was saturated and 
other factors increasing the exposure of BPA at high doses. 
Previously, Doerge et al. (2010) showed that BPA displays lin-
ear dose-exposure relationship between doses of 50 to 200 
μg/kg in rodents. Doses we employed were much higher than 
this range and different pattern was anticipated. BPA under-
goes extensive phase II metabolism to glucuronide or sulfate-
conjugated forms (Doerge et al., 2010) and in rodents, biliary 
excretion was predominant, which was corroborated by the 
appearance of second Cmax peaks alluding entero-hepatic re-
circulation. This shall increase the systemic exposure of BPA 
to the extent exceeding dose-proportion (e.g. Cmax at 250 mg/
kg in male on day 1 was 146,219.7 nM, almost 10,000 fold of 
Cmax at 0.5 mg/kg, 14.7 nM even though dose was 500 fold). 
Cmax and AUC of BPA were considerably lower at the time of 
day 91 compared to day 1, reflecting that juvenile animals may 
be much more susceptible to BPA exposure which might be 
attributable to metabolic inefficiency. 
We demonstrated that repeated oral treatment of BPA to 
the juvenile rats from the post-natal day 9 for 90 days caused 
increases in body weights and food consumption, and pre-
mature female sexual development. The increases of body 
weight achieved a statistical significance at 5 mg/kg in male 
rats which were apparent from 6 weeks of dosing, about the 
time when the puberty of rats starts (Leibowitz et al., 2009), 
and persisted through the adulthood until the end of the 
study. Interestingly, these effects were of a non-linear dose-
response relationship in which higher doses, 50 or 250 mg/
kg, only showed marginal differences, demonstrating the non-
monotonic dose-effect relationship of BPA-induced health ef-
fects and at the same time, importance of low-dose effects. 
Collectively, we demonstrated that repeated oral exposure to 
BPA in juvenile rats led to bile duct proliferation, which may 
support the higher risk of BPA exposure in younger genera-
tions. Greater exposure in this age group may attribute to bile 
duct proliferation by low-dose BPA, at least in part, which calls 
for further studies in the future.
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Fig. 4. Toxicokinetic profiles of BPA on day 1 and 91 after repeat dose. Plasma concentrations of BPA of male (A) and female rats (B) on 
day 1, and male (C) and female rats (D) on day 91. Data are mean ± SD of 10 animals.
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